Umeclidinium And Vilanterol

Introduction Overview

Generic Name

umeclidinium and vilanterol

Brand Name

Anoro Ellipta

Dosage Form

inhalation powder (62.5 mcg-25 mcg/inh)

Drug Class

Bronchodilator combinations

Pharmacokinetics

Absorption:
Umeclidinium and vilanterol are administered via inhalation, which allows for direct delivery to the airways with rapid local effects and reduced systemic exposure compared to oral administration. Umeclidinium is a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta-2 adrenergic receptor agonist (LABA). Upon inhalation, a portion of the drug deposits in the lungs allowing quick onset of action, while some portion may be swallowed and undergoes minimal systemic absorption from the gastrointestinal tract. Due to low oral bioavailability, the systemic exposure is predominantly from pulmonary absorption. Clinical pharmacokinetic studies have demonstrated umeclidinium achieves maximum plasma concentrations within approximately 5 to 15 minutes post-inhalation, while vilanterol peaks around 5 to 20 minutes, supporting rapid bronchodilation onset.

Distribution:
Both umeclidinium and vilanterol bind moderately to plasma proteins, influencing their distribution volume. Umeclidinium exhibits moderate tissue distribution, with notable affinity for lung tissues due to inhaled administration. Vilanterol similarly shows extensive distribution in the respiratory tract with systemic distribution limited by its rapid clearance. Volume of distribution estimates indicate a relatively large distribution for umeclidinium, reflecting tissue binding outside the vascular compartment. Neither drug extensively crosses the blood-brain barrier, minimizing central nervous system side effects. The inhaled route also limits systemic distribution initially, targeting the drug action primarily to lung tissues.

Metabolism:
Umeclidinium is extensively metabolized primarily by cytochrome P450 enzymes, mainly CYP2D6 and CYP3A4, undergoing oxidative biotransformation to inactive metabolites eliminated in urine and feces. Vilanterol is also metabolized predominantly via CYP3A4-mediated oxidation, yielding metabolites with negligible pharmacologic activity. The metabolic pathways for both drugs involve hepatic processing with minimal formation of active metabolites. Drug interactions with strong CYP3A4 inhibitors or inducers can potentially alter plasma concentrations, necessitating clinical awareness and monitoring.

Elimination:
Elimination of umeclidinium and vilanterol primarily occurs through biliary and renal pathways. The inactive metabolites of umeclidinium are excreted mainly via feces (~58%) and urine (~22%), reflecting hepatobiliary clearance. Vilanterol metabolites are similarly eliminated predominantly through fecal excretion. The elimination half-life supports once-daily dosing, with umeclidinium having a terminal half-life of approximately 11 hours and vilanterol approximately 21 hours. The prolonged half-life correlates with sustained receptor binding and bronchodilator effect, suitable for maintenance therapy in COPD. Impaired hepatic or renal function may influence elimination but no dosage adjustment is typically required.

Dosage Forms

Available Dosage Forms:
Umeclidinium and vilanterol is available as an inhalation powder delivered via the Ellipta dry powder inhaler device. The marketed dosage form contains a combination of umeclidinium 62.5 micrograms and vilanterol 25 micrograms per inhalation. This fixed-dose combination is designed for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD).

Dosages for Adults and Adolescents:
The recommended dose for adults with COPD is one inhalation of the 62.5 mcg umeclidinium and 25 mcg vilanterol combination once daily. The dosing regimen emphasizes consistency — the medication should be used at the same time every day with a maximum frequency of one inhalation per 24 hours. There are no approved indications or dosing recommendations for use in pediatric populations or adolescents under 18 years of age.

Specific Patient Populations:
The inhalation powder formulation has not been formally studied or approved for patients under 18 years old, and its use in this group is not recommended. No specific dose adjustment is generally required for patients with mild to moderate hepatic or renal impairment, but caution is advised in severe cases due to possible altered systemic exposure. Elderly patients do not require dose adjustments, but should be carefully monitored for anticholinergic side effects. Administration must avoid use in individuals with known hypersensitivity to milk proteins due to lactose excipient in the formulation.

Mechanism Of Action

Umeclidinium and vilanterol combine two complementary bronchodilator mechanisms facilitating sustained airway relaxation in COPD patients. Umeclidinium acts as a long-acting muscarinic antagonist (LAMA) that competitively blocks acetylcholine at M3 muscarinic receptors on airway smooth muscle. This inhibition prevents bronchoconstriction mediated by parasympathetic nerve activation, leading to persistent relaxation of the bronchial musculature and decreased airflow obstruction. Through sustained receptor blockade, umeclidinium provides a prolonged bronchodilatory effect, typically lasting 24 hours, reducing daily symptoms and improving airflow.

In parallel, vilanterol is a long-acting beta-2 adrenergic receptor agonist (LABA) that selectively stimulates beta-2 receptors on airway smooth muscle cells. This activation increases intracellular cyclic AMP via adenylate cyclase stimulation, promoting smooth muscle relaxation by inhibiting calcium release and myosin light chain kinase activity. Vilanterol’s potent and selective beta-2 adrenergic activation leads to extended bronchodilation also lasting up to 24 hours, enhancing airflow and reducing bronchospasm.

The combination of these two agents provides dual and complementary pathways for bronchodilation: muscarinic receptor antagonism reduces cholinergic bronchoconstriction, while beta-2 stimulation actively relaxes bronchial smooth muscle. This synergistic action produces superior improvements in lung function versus either agent alone, with reduced symptoms of COPD and lowered exacerbation frequency. Clinical trials have demonstrated that this combination improves forced expiratory volume and reduces rescue inhaler use.

From a clinical perspective, unlike short-acting bronchodilators, the umeclidinium-vilanterol combination is not intended for acute relief but for maintenance therapy. It is formulated as a once-daily inhalation powder, facilitating patient adherence. Compared to other long-acting bronchodilators, like tiotropium or formoterol alone, the dual action supports more comprehensive control of airflow obstruction. Research supports the safety and efficacy of this combination, with ongoing studies exploring its role in COPD management guidelines.

Pharmacological Actions

Long-acting muscarinic antagonist activity by umeclidinium inhibiting M3 receptors on airway smooth muscle resulting in bronchodilation
Long-acting beta-2 adrenergic receptor agonist action by vilanterol elevating intracellular cAMP and facilitating airway smooth muscle relaxation
Synergistic and complementary bronchodilator effects leading to sustained, once-daily airway dilation
Reduction of bronchospasm, airflow obstruction, and hyperinflation in COPD patients
Improvement of lung function parameters such as FEV1 and quality of life in chronic obstructive pulmonary disease
Prolonged duration of action (up to 24 hours) supporting maintenance therapy compliance
No significant anti-inflammatory effects as the combination lacks corticosteroid activity
Minimal systemic anticholinergic and adrenergic adverse effects at therapeutic doses due to inhaled route and direct pulmonary delivery
Suitable for patients intolerant or unresponsive to monotherapy with either a LAMA or LABA alone
Once-daily dosing regimen improving adherence and simplifying COPD management
No significant central nervous system penetration, lowering risk of neuropsychiatric effects
Does not provide rapid relief of acute bronchospasm; not approved as rescue medication

Therapeutic Or Clinical Uses

Maintenance treatment to prevent airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD)
Management and improvement of symptoms associated with COPD including chronic bronchitis and emphysema
Reduction of frequency and severity of COPD exacerbations
Improvement in forced expiratory volume in 1 second (FEV1) and overall lung function in COPD patients
Enhancement of exercise tolerance and reduction of breathlessness in COPD
Alternative or adjunct to monotherapy with long-acting bronchodilators when symptoms persist
Not indicated for the treatment of asthma and should not be used to relieve acute bronchospasm
Not intended as rescue medication during COPD exacerbations
Helps to decrease reliance on short-acting beta-2 agonist rescue inhalers in COPD management
Support for once-daily inhalation regimen aims to improve patient compliance and long-term clinical outcomes
Potential use in patients intolerant to inhaled corticosteroids or those wishing to avoid steroid-related side effects
Useful in patients with moderate to severe COPD requiring sustained bronchodilation
May be used in combination with other COPD therapies as directed by healthcare providers
Appropriate for both ambulatory and stable COPD patients as part of comprehensive disease management

Side Or Adverse Effects

Upper respiratory tract symptoms such as stuffy nose, sinus pain, and sore throat
Chest pain and cough following inhalation
Gastrointestinal disturbances including diarrhea and constipation
Muscle spasms and musculoskeletal pain affecting neck, arms, or legs
Potential for blurred vision, tunnel vision, eye pain or redness, or visual halos indicating possible glaucoma exacerbation
Urinary retention or difficulty urinating, particularly in patients with pre-existing prostatic hypertrophy
Wheezing, choking, or other paradoxical bronchospasm reactions after using the inhaler
Hyperglycemia symptoms such as increased thirst, frequent urination, unexplained hunger, and sweet-smelling breath
Hypokalemia manifestations including leg cramps, muscle weakness, palpitations, or irregular heartbeats
Allergic reactions potentially including hives, facial or throat swelling, difficulty breathing, which require immediate medical attention
Tachycardia or palpitations related to beta-2 agonist activity
Headache and dizziness
Dry mouth related to anticholinergic effects
Rare but serious side effects such as cardiac arrhythmias
Potential for worsening of narrow-angle glaucoma due to anticholinergic effects

Precautions

Contraindicated in patients with known hypersensitivity to umeclidinium, vilanterol, or milk proteins present in the formulation
Not recommended for treatment or relief of acute bronchospasm or as a rescue inhaler
Use with caution in patients with cardiovascular disorders such as coronary artery disease, arrhythmias, or hypertension
Monitor patients with a history of seizures as beta-2 agonists may lower seizure threshold
Caution advised in patients with glaucoma or increased intraocular pressure as umeclidinium may exacerbate these conditions
Careful use in patients with urinary retention or prostatic hypertrophy due to anticholinergic effects leading to worsened symptoms
Monitor blood glucose and potassium levels in diabetic patients or those with electrolyte imbalances
Avoid concomitant use with other LABA-containing products to reduce risk of overdose and adverse cardiovascular events
Not studied in children or adolescents under 18; safety and efficacy in this population not established
Potential interaction with CYP3A4 inhibitors requiring clinical monitoring for altered plasma concentrations
Storage of inhaler device in original sealed foil tray until use to maintain medication stability
Discard inhaler 6 weeks after opening or when dose indicator reaches zero to ensure drug potency
Inform patients about correct inhaler technique to maximize therapeutic benefit
Patients with liver or kidney impairment should use cautiously and under medical supervision

Warnings

Do not use if allergic to umeclidinium, vilanterol, or milk proteins contained in the inhaler
This medication is not a rescue treatment; it will not relieve acute bronchospasm or sudden breathing difficulty
Seek immediate medical attention if breathing problems worsen or symptoms escalate rapidly despite use
Serious allergic reactions (anaphylaxis) can occur—watch for hives, swelling of face or throat, difficulty breathing
Paradoxical bronchospasm may occur which can be life-threatening; discontinue and seek emergency help if it happens
Use caution in patients with pre-existing cardiovascular conditions due to potential increase in heart rate or arrhythmias
Increased risk of hyperglycemia and hypokalemia with systemic beta-2 agonist effects, requiring monitoring
Avoid using multiple LABA-containing drugs concurrently due to risk of additive side effects
Not studied or approved for pediatric use; safety concerns in this population
Pregnancy and breastfeeding safety has not been fully established; use only if benefits outweigh risks
Withdraw therapy cautiously to avoid exacerbation of COPD symptoms
Improper inhaler use can diminish effectiveness and increase risk of adverse effects
Discontinue if signs of ocular pressure increase or urinary retention appear
Patients should be informed about the importance of adherence to once-daily dosing without exceeding recommended frequency

Contraindication

Known hypersensitivity to umeclidinium or vilanterol
Severe allergy to milk proteins present as excipients in the inhaler formulation
Use in pediatric patients under 18 years of age
Use as a rescue therapy for acute bronchospasm or asthma attacks
Concurrent use with other LABA-containing medications to avoid overdose
Patients with hypersensitivity to any of the product components
Severe narrow-angle glaucoma where anticholinergic effect exacerbates intraocular pressure
Urinary retention not controlled or severe prostate hypertrophy
Acute episodes of COPD exacerbations where short-acting bronchodilators and steroids are first line
Known intolerance or prior severe adverse reactions to inhaled bronchodilator combinations

Drug Interactions

Concurrent use with other long-acting beta-2 agonists (formoterol, salmeterol, olodaterol, arformoterol, indacaterol, vilanterol) increases risk of cardiovascular side effects and overdose
CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of vilanterol, requiring careful monitoring
Beta-blockers may antagonize the bronchodilatory effects of vilanterol and reduce efficacy
Anticholinergic drugs like atropine may have additive antimuscarinic effects with umeclidinium, increasing side effects such as dry mouth or urinary retention
Monoamine oxidase inhibitors and tricyclic antidepressants may enhance cardiovascular effects of vilanterol, increasing risk for arrhythmias
Medications that prolong QT interval may increase risk of cardiac arrhythmias when combined with vilanterol
Antifungal and antiviral agents might alter hepatic metabolism of the components via CYP450 modulation
Cold and allergy medications with anticholinergic or adrenergic properties can potentiate additive side effects
Drugs for Parkinson’s disease (anticholinergics) may augment antimuscarinic adverse effects
Medications for motion sickness or irritable bowel syndrome with anticholinergic properties may also exacerbate side effects
Other overactive bladder treatments could increase urinary retention risk when combined
Depression or mood disorder drugs with serotonergic activity may necessitate monitoring for interactions
Herbal supplements affecting CYP450 enzymes or adrenergic pathways could alter drug levels or effects
Patients should inform healthcare providers of all prescription, over-the-counter, and herbal products to avoid interactions

Preparations Of The Drug

Combination inhalation powder administered via the Ellipta dry powder inhaler device
Single fixed-dose product containing umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation
Packaged in sealed foil trays to maintain dry powder stability prior to first use
Disposable inhaler device designed for once-daily administration with a dose counter indicator
Contains lactose as an excipient, which may be problematic for patients with severe milk protein allergy
Intended for oral inhalation only with no products for nebulization or oral/IV formulations
No currently approved generic formulations available; marketed under brand name Anoro Ellipta
Each inhaler trialed for dose consistency and particle size distribution to ensure optimal lung delivery
Shipped and stored at room temperature away from moisture, heat, and direct light to protect powder integrity
Discard inhaler 6 weeks after opening or when dose counter reaches zero, whichever occurs first